Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (20)

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

    Therapeutic Advances in Medical Oncology, Vol. 11

  4. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  2. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME)

    International Journal of Colorectal Disease, Vol. 33, Núm. 2, pp. 241-249

  3. The Spanish Society of Cytology: Quality control program of gynecological cytology

    Revista Espanola de Patologia, Vol. 51, Núm. 2, pp. 71-76

2017

  1. Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis

    Frontiers in Oncology, Vol. 7, Núm. DEC

  2. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407

2016

  1. Measurement of total and free docetaxel concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 117, pp. 140-149

2015

  1. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies

    Oncotarget, Vol. 6, Núm. 42, pp. 44254-44273

2014

  1. VAV3 mediates resistance to breast cancer endocrine therapy

    Breast Cancer Research, Vol. 16, Núm. 3

2013

  1. Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

    Cell Cycle, Vol. 12, Núm. 2, pp. 225-245

2012

  1. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment

    Oncotarget, Vol. 3, Núm. 12, pp. 1600-1614

  2. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

    Breast Cancer Research and Treatment, Vol. 134, Núm. 3, pp. 1161-1168

  3. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis

    Cancer Research, Vol. 72, Núm. 11, pp. 2879-2888

2011

  1. Evidence for a link between TNFRSF11A and risk of breast cancer

    Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954

2010

  1. Positive sentinel node risk in relation to oestrogen receptors in breast cancer in premenopausal and postmenopausal women

    Revista Espanola de Medicina Nuclear, Vol. 29, Núm. 6, pp. 289-292

2009

  1. Removal of the internal mammary sentinel node in breast cancer

    Nuclear Medicine Communications, Vol. 30, Núm. 12, pp. 962-970

2004

  1. Treatment of malignant superior vena cava syndrome by endovascular stent insertion: Experience on 52 patients with lung cancer

    Lung Cancer, Vol. 43, Núm. 2, pp. 209-214